Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma

Mark Lipstein, Owen O'Connor, Francesca Montanari, Luca Paoluzzi, Danielle Bongero, Govind Bhagat

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.

Original languageEnglish (US)
Pages (from-to)E43-E46
JournalClinical Lymphoma, Myeloma and Leukemia
Volume10
Issue number5
DOIs
StatePublished - Oct 1 2010
Externally publishedYes

Fingerprint

Tumor Lysis Syndrome
HIV
Lymphoma
Lymphoma, Large B-Cell, Diffuse
Multiple Myeloma
Therapeutics
Bortezomib
Plasmablastic Lymphoma

Keywords

  • Diffuse large B-cell lymphoma
  • Non-Hodgkin lymphoma
  • R-CHOP

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. / Lipstein, Mark; O'Connor, Owen; Montanari, Francesca; Paoluzzi, Luca; Bongero, Danielle; Bhagat, Govind.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 10, No. 5, 01.10.2010, p. E43-E46.

Research output: Contribution to journalArticle

Lipstein, Mark ; O'Connor, Owen ; Montanari, Francesca ; Paoluzzi, Luca ; Bongero, Danielle ; Bhagat, Govind. / Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. In: Clinical Lymphoma, Myeloma and Leukemia. 2010 ; Vol. 10, No. 5. pp. E43-E46.
@article{d18538492ce74dd191990303d80f4731,
title = "Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma",
abstract = "Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.",
keywords = "Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma, R-CHOP",
author = "Mark Lipstein and Owen O'Connor and Francesca Montanari and Luca Paoluzzi and Danielle Bongero and Govind Bhagat",
year = "2010",
month = "10",
day = "1",
doi = "10.3816/CLML.2010.n.074",
language = "English (US)",
volume = "10",
pages = "E43--E46",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "5",

}

TY - JOUR

T1 - Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma

AU - Lipstein, Mark

AU - O'Connor, Owen

AU - Montanari, Francesca

AU - Paoluzzi, Luca

AU - Bongero, Danielle

AU - Bhagat, Govind

PY - 2010/10/1

Y1 - 2010/10/1

N2 - Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.

AB - Plasmablastic lymphoma (PBL) is an aggressive lymphoma classified by the World Health Organization as a subtype of diffuse large B-cell lymphoma that shares many morphologic and immunophenotypic features with multiple myeloma. It is extremely rare in immunocompetent patients. Because of the small number of patients reported, this rare lymphoma remains a poorly characterized and understood entity with presently no standard recommendations regarding the optimal treatment. Herein, we report a dramatic clinical response coupled with tumor lysis syndrome to a bortezomib-based treatment in an HIV-negative patient with refractory plasmablastic lymphoma.

KW - Diffuse large B-cell lymphoma

KW - Non-Hodgkin lymphoma

KW - R-CHOP

UR - http://www.scopus.com/inward/record.url?scp=79952996426&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952996426&partnerID=8YFLogxK

U2 - 10.3816/CLML.2010.n.074

DO - 10.3816/CLML.2010.n.074

M3 - Article

C2 - 21856550

AN - SCOPUS:79952996426

VL - 10

SP - E43-E46

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 5

ER -